No. of patients
Overall Survival
Subgroups
a
Nivolumab
IC
Unstratified Hazard Ratio (95% CI)
Overall
240
121
0.69 (0.53, 0.91)
Age category, years
<65
172
76
0.64 (0.45, 0.89)
≥65 to <75
56
39
0.93 (0.56, 1.54)
≥75
12
6
ECOG performance status
0
49
23
0.60 (0.30, 1.23)
≥1
190
97
0.71 (0.53, 0.96)
Tobacco use
Current/Former
191
85
0.71 (0.52, 0.99)
Never
39
31
0.58 (0.32, 1.06)
Prior lines of systemic therapy, n
1
106
58
0.72 (0.48, 1.07)
2
80
45
0.64 (0.40, 1.00)
≥3
54
18
0.77 (0.38, 1.57)
Intended IC therapy
Methotrexate
119
52
0.64 (0.43, 0.96)
Docetaxel
88
54
0.82 (0.53, 1.28)
Cetuximab
33
15
0.47 (0.22, 1.01)
0.125
0.25
0.5
1
2
a
Hazard ratios were not calculated for subgroups
